(Q36889170)

16 August 2017

1 reference

title

How can we prevent cardiovascular disease in diabetes (English)

1 reference

16 August 2017

main subject

cardiovascular disease

1 reference

Wiklund O

1

1 reference

16 August 2017

Håversen L

series ordinal

2

1 reference

16 August 2017

Pettersson C

series ordinal

3

1 reference

16 August 2017

Hultén LM

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Journal of Internal Medicine

16 August 2017

published in

1 reference

16 August 2017

volume

262

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

199-207

1 reference

The global burden of disease, 1990–2020

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The extracellular matrix on atherogenesis and diabetes-associated vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

What is so special about apolipoprotein AI in reverse cholesterol transport?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

New insights into the regulation of HDL metabolism and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Antiinflammatory properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Lipid inflammatory mediators in diabetic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Antiatherogenic properties of fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The potential for CETP inhibition to reduce cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

CETP inhibition in cardiovascular risk management: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Morphological characteristics of coronary atherosclerosis in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Advanced glycation end products: sparking the development of diabetic vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

RAGE axis: Animal models and novel insights into the vascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Adipose tissue, adipokines, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Adipose tissue and atherosclerosis: exploring the connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2007.01828.X

10.1111/J.1365-2796.2007.01828.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference